Stevanato Group cuts 2027 growth guidance on GLP-1 customer shift
Stevanato Group told the Jefferies Global Healthcare Conference on 18 November 2026 that it now expects low single-digit growth in 2027, down from a prior range of high single-digit to low double-digit. The Italian pharmaceutical packaging and drug delivery group learned in October that one major GLP-1 originator customer had lowered its 2027 demand forecast and expects higher inventory. Stevanato says it has already backfilled about 90% to 100% of the lost GLP-1 revenue through other products and customers. Management still expects margin expansion and a step-up in free cash flow in 2027.
Why this mattersA guidance cut tied to a single GLP-1 customer underscores how concentrated pharma-packaging suppliers remain exposed to swings in originator demand forecasts.
- Stevanato cut its 2027 growth outlook to low single-digit from a prior high single-digit to low double-digit range
- The cut follows a lower 2027 demand forecast and higher expected inventory at one major GLP-1 originator customer, which Stevanato learned of in October 2026
- The second GLP-1 originator customer raised its 2027 outlook, according to the company
- Stevanato says about 90% to 100% of the lost GLP-1 revenue has been backfilled through other products and customers
- The lost volume came from a high-volume syringe programme with gross margins in the 40% range
- Management still expects margin expansion and a step-up in free cash flow in fiscal 2027